Compound that prevents replication of SARS-CoV-2 identified by researchers
Researchers say that the Ebselen compound can inhibit the replication of SARS-CoV-2 in the laboratory, so could combat COVID-19.
List view / Grid view
Researchers say that the Ebselen compound can inhibit the replication of SARS-CoV-2 in the laboratory, so could combat COVID-19.
Researchers have found a compound that can prevent up-regulation of CD14, a key inflammatory protein, in cells.
This article summarises the development and testing of a novel vaccine that could be personalised for the treatment of immunotherapy-resistant cancers, such as triple-negative breast cancer (TNBC).
Researchers say this is the first time that CRISPR-Cas9 gene editing has been used to treat cancer effectively in a living animal and that the technique could be revolutionary.
The candidates were screened based on their similarity to hydroxychloroquine and tested for efficacy against SARS-CoV-2 in vitro.
Researchers have found that neutralising antibodies for the TNF-alpha and IFN-gamma cytokines can prevent death from SARS-CoV-2 in mice.
Researchers say their new process enables the synthesis of phenazinones, some of which have high selective toxicity for cancer cells and could be promising anticancer drugs in future.
Researchers have found that CBD induces an enzyme with antioxidant and anti-inflammatory properties in the top layer of the skin.
Researchers demonstrate that inhibiting the LMTK3 kinase is an effective anticancer strategy in murine models of breast cancer.
The tool uses interactive molecular dynamics simulations in virtual reality (iMD-VR) to allow researchers to step inside SARS-CoV-2 enzymes and visualise molecules binding to them.
Researchers have identified that autoreactive B cells and a protein that enables them to invade joints could be promising drug targets for the most common inflammatory arthritis.
Three separate studies have identified nanobodies – a miniature form of antibodies found in camelid species – that can bind to the SARS-CoV-2 Spike (S) protein and neutralise the virus in cells.
The synthetic protein nanoparticle can cross the blood-brain barrier and deliver a targeted therapeutic to glioblastoma cells, say researchers.
Using their de novo protein design strategy, researchers engineered human angiotensin converting enzyme 2 (hACE2) protein decoys that can protect cells from SARS-CoV-2 infection.
Scientists have developed a new antibody-drug conjugate (ADC), made from ICAM1, an antibody that targets pancreatic cancer and the cytotoxic drug DM1 (mertansine).